Entreprise de R&D engagée dans l’innovation scientifique pour la prévention et la lutte contre les maladies métaboliques et cardiovasculaires.
Location: France, Auvergne-Rhône-Alpes, Riom
Employees: 11-50
Phone: +33 5 46 28 62 58
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | AQUITI Ges... | aquiti.fr |
Mentions in press and media 15
| Date | Title | Description |
| 30.09.2021 | VALBIOTIS : Publication of 2021 half-year results | Valbiotis reviews its activities and publishes its financial report for the first half of 2021 TOTUM•63, prediabetes Obtaining of the patent in China; Scientific publications validating the R&D work performed; Announcement of the implem... |
| 24.09.2021 | Microalgae: exclusive agreement with IFREMER and ADECAL Technopole | Valbiotis consolidates its development of innovative natural health solutions by integrating the exploration of microalgae produced in New Caledonia, through an exclusive agreement with ADECAL-Technopole and IFREMER This tripartite agreemen... |
| 09.09.2021 | VALBIOTIS : Release of Letter to Shareholders for 2021 | Valbiotis releases its Letter to Shareholders for 2021 La Rochelle, September 9, 2021 (5:40 p.m. CEST) - Valbiotis (FR0013254851 - ALVAL, PEA/SME eligible), a French research and development company committed to scientific innovation for pr... |
| 06.09.2021 | VALBIOTIS : Completion of recruitment for the Phase II HEART clinical study conducted with TOTUM•070 | Valbiotis announces the completion of recruitment for the Phase II HEART clinical study conducted with TOTUM•070 in hypercholesterolemia, a risk factor for cardiovascular disease Recruitment of the last volunteer, randomized at the beginnin... |
| 28.06.2021 | VALBIOTIS : Implementation of the TOTUM•63 mode of action clinical study by INAF at Laval University in Quebec City | Valbiotis announces the implementation of the TOTUM•63 mode of action clinical study by INAF1 at Laval University in Quebec City, in partnership with Nestlé Health Science The TOTUM•63 mode of action clinical study was co-designed by Valbio... |
| 07.06.2021 | VALBIOTIS VALBIOTIS : Appointment of Sébastien BESSY as Chief Operating Marketing and Business Officer | Valbiotis appoints Sébastien Bessy, international expert in Consumer Healthcare, as Chief Operating Marketing and Business Officer Previously Vice-President Global Strategic Operations Consumer Healthcare at Ipsen, with over 20 years of exp... |
| 03.06.2021 | VALBIOTIS VALBIOTIS : Publication of the first scientific papers on TOTUM•63 in three international journals | Valbiotis announces the publication of the first scientific papers on TOTUM•63 in three international journals, elucidating its multitarget mode of action The scientific papers, presenting preclinical and clinical Phase I/II results for TOT... |
| 26.05.2021 | VALBIOTIS Valbiotis : granted a 1.25 million innovation support loan by Bpifrance | Valbiotis granted a €1.25 million innovation support loan by Bpifrance Research & Development innovation loan: €750,000. Investment seed loan: €500,000. La Rochelle, May 26, 2021 (5:40 pm CEST) - Valbiotis (FR0013254851 - ALVAL, eligibl... |
| 12.05.2021 | Valbiotis :' Combined General Meeting on May 27, 2021 Will Exceptionally Be Held Behind Closed Doors | Regulatory News: Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces that, exceptionally, its C... |
| 12.05.2021 | VALBIOTIS Valbiotis : rsquo; Combined General Meeting on May 27, 2021 will exceptionally be held behind closed doors | Valbiotis' Combined General Meeting on May 27, 2021 will exceptionally be held behind closed doors Shareholders are invited to vote remotely La Rochelle, May 12, 2021 (5:40 pm CEST) - Valbiotis (FR0013254851 - ALVAL, eligible for the PEA/SM... |
Show more